The ongoing development of pharmacologic agents such as the EZH2 inhibitor (tazemetostat), the oxidative phosphorylation inhibitor (IACS-01759), and CDK4/6 inhibitors (palbociclib) may offer promising therapeutic options for patients with SMARCA4-deficient NSCLC, potentially improving clinical outcomes.[13,24–26]. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.